Search - tctmd.com

Displaying 961 - 980 of 1172

Sort: Relevancy | Date

News Daily News

Risk Peaks Early After Clopidogrel Cessation in SVG PCI Patients

November 13, 2012

News Industry News

Significantly Better Patient Outcomes Gained from Pacing Both Ventricles in Patients with AV Block and Reduced Pumping Function

November 05, 2012

News Conference News AHA 2012

No Mortality Benefit with Prolonged Dual Antiplatelet Therapy

November 05, 2012

News Conference News TCT 2012

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

November 02, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 31, 2012

News Industry News

Boston Scientific Receives CE Mark Approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System, Featuring A Novel Bioabsorbable Polymer Coating

October 31, 2012

News Industry News

Study Finds Drug-Eluting Stents Exhibit Some Benefits Over Bare-Metal Stents In Patients Over 80, Though Both Demonstrate Clinical Benefit

October 26, 2012

News Conference News TCT 2012

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

October 26, 2012

News Conference News TCT 2012

ADAPT-DES: Poor Clopidogrel Response Not Predictive of 1-Year Mortality

October 25, 2012

News Industry News

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

October 25, 2012

News Industry News

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

October 24, 2012

News Industry News

PROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy

October 24, 2012

News Conference News TCT 2012

Promising Outlook for Bioabsorbable Scaffolds, Polymers in Next-Generation Stents

October 24, 2012

News Conference News TCT 2012

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

October 24, 2012

News Conference News TCT 2012

DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS

October 24, 2012

News Conference News TCT 2012

DES: The Year in Review

October 23, 2012

News Conference News TCT 2012

DAPT Cessation Within 1 Year Increased Risk for Major Adverse Events

October 23, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 22, 2012

News Industry News

Analysis Of Medtronic Stent Finds Early Cessation Of Dual Antiplatelet Therapy Caused No Increased Risk Of Blood Clots To One Year

October 22, 2012

News Daily News

New Class of Oral Anticoagulants Safer Compared with Warfarin for A-fib

October 19, 2012

Advertisement

Risk Peaks Early After Clopidogrel Cessation in SVG PCI Patients

Significantly Better Patient Outcomes Gained from Pacing Both Ventricles in Patients with AV Block and Reduced Pumping Function

No Mortality Benefit with Prolonged Dual Antiplatelet Therapy

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

Boston Scientific Receives CE Mark Approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System, Featuring A Novel Bioabsorbable Polymer Coating

Study Finds Drug-Eluting Stents Exhibit Some Benefits Over Bare-Metal Stents In Patients Over 80, Though Both Demonstrate Clinical Benefit

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

ADAPT-DES: Poor Clopidogrel Response Not Predictive of 1-Year Mortality

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

PROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy

Promising Outlook for Bioabsorbable Scaffolds, Polymers in Next-Generation Stents

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS

DES: The Year in Review

DAPT Cessation Within 1 Year Increased Risk for Major Adverse Events

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

Analysis Of Medtronic Stent Finds Early Cessation Of Dual Antiplatelet Therapy Caused No Increased Risk Of Blood Clots To One Year

New Class of Oral Anticoagulants Safer Compared with Warfarin for A-fib

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content